Samira Shaikhly Sells 2,178 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 2,178 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at $27,897.74. This represents a 73.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Samira Shaikhly also recently made the following trade(s):

• On Friday, June 12th, Samira Shaikhly sold 6,250 shares of Septerna stock. The shares were sold at an average price of $35.08, for a total transaction of $219,250.00.
• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The stock was sold at an average price of $28.93, for a total transaction of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Trading Down 3.6%

Septerna stock traded down $1.26 during midday trading on Tuesday, reaching $33.49. 747,642 shares of the stock traded hands, compared to its average volume of 338,290. Septerna, Inc. has a fifty-two week low of $10.30 and a fifty-two week high of $37.99. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -41.35 and a beta of 2.39. The firm has a fifty day moving average price of $29.43 and a two-hundred day moving average price of $27.43.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The company had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. Analysts anticipate that Septerna, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Septerna

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Woodline Partners LP boosted its stake in Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares in the last quarter. Rhumbline Advisers lifted its holdings in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after acquiring an additional 3,323 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after purchasing an additional 78,316 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares in the last quarter. Finally, CW Advisors LLC acquired a new position in shares of Septerna in the 2nd quarter worth approximately $133,000.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Raymond James Financial upped their price objective on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. Wells Fargo & Company increased their target price on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. Truist Financial raised their target price on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Septerna has a consensus rating of “Moderate Buy” and an average price target of $45.78.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.